Can Equitable Access To Monoclonal Antibody Therapies In LMICs Ever Be Attained? This Group Believes So... And So Do We

July 22, 2024: Kigali, Rwanda and San Francisco, USA

In their recent paper (Malhotra et al 2024) Shelly Malhotra and colleagues provide an excellent distillation of the challenges surrounding equitable access to powerful monoclonal antibody - based (mAb) therapies in Low-Middle Income Countries (LMICs), despite their having been standard-of-care in higher income countries for decades. What distinguishes this article is that the authors take a deeper look into the issues that drive the well-known affordability barriers, to suggest enabling solutions that are both impactful and feasible. The content is weighted slightly more toward mAbs for emergent, infectious diseases (IDs) (for which outbreaks can be unpredictable and/or episodic), but many of the points are nonetheless equally relevant to mAbs for non-communicable diseases (NCDs) for which epidemiological dynamics are more predictable.

Download for more details.